Please login to the form below

Not currently logged in
Email:
Password:

Sanofi launches community health project in China

Partners with local associations to improve chronic disease management
Sanofi

Sanofi has launched a strategic health initiative in China that aims to improve community-level management of chronic diseases.

The French pharma company said it created the Healthy Community Project as a response to the Chinese government's call to strengthen community healthcare - one of the country's healthcare reform goals.

The venture will see Sanofi partner with four local organisations - the Chinese Medical Doctor Association, Community Health Association of China, China International Exchange, and Promotive Association for Medical and Health Care.

In doing so the company hopes to improve the multi-tiered healthcare approach to chronic disease management in 42 cities across China.

Jean-Christophe Pointeau, Sanofi China's general manager of pharma, described the project as “one of the most strategically important” in China.

He added: “The Healthy Community Project gathers the best of our resources and is committed to providing community healthcare professionals with the most comprehensive solutions and platform for know-how knowledge.”

Sanofi will work with community healthcare centres, HCPs and patients alike, sharing best practises of chronic disease management to help improve managerial expertise, clinical skills and self-management capabilities.

There is an urgent need for early diagnosis and treatment of chronic diseases in China, with 290 million people suffering from cardiovascular diseases and 114 million from diabetes – the country's two most prevalent chronic diseases.

The first phase of the project, focusing on cardiovascular and diabetes patients, has already been put into operation, and Sanofi hopes that its Healthy Community Project will reach 30,000 community physicians and 23 million patients by 2020.

The venture may also go some way to rebuilding pharma's strained relations with Chinese authorities, following the 2013 GSK corruption scandal that subsequently drew in Roche, Sanofi and a number of other pharma firms.

Article by
Rebecca Clifford

16th June 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...